CN103494832A - Compound ivermectin albendazole transdermal agent for livestock and application method thereof - Google Patents
Compound ivermectin albendazole transdermal agent for livestock and application method thereof Download PDFInfo
- Publication number
- CN103494832A CN103494832A CN201310453797.6A CN201310453797A CN103494832A CN 103494832 A CN103494832 A CN 103494832A CN 201310453797 A CN201310453797 A CN 201310453797A CN 103494832 A CN103494832 A CN 103494832A
- Authority
- CN
- China
- Prior art keywords
- albendazole
- ivermectin
- transdermal agent
- transdermal
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention belongs to the technical field of preparation of medicament for livestock, and particularly relates to a compound ivermectin albendazole transdermal agent for livestock and an application method thereof. The transdermal agent is a mixture of two or three components below at any proportion: ivermectin, albendazole, solubilizer tween-80, a laurocapram transdermal accelerant, a 95% ethanol diluent, an N-methyl-pyrrolidone and propylene glycol. When the transdermal agent is used for treating parasitic diseases of animals such as pigs and sheep, the transdermal agent is flow-coated from the head part to the tail root part along a dorsal line after hairs at the back part are uniformly pushed aside towards two sides, and good treatment effect can be obtained after the transdermal agent is used continuously for three days. The preparation method of the compound ivermectin albendazole transdermal agent for livestock is simple; in comparison with other dosage form in the prior art, the medicine use way is simpler and more convenient, and more dosage is saved; as no liver first-pass effect exists, influence from gastric emptying rate and the like is avoided, the irritability reaction degree of the animals is low, the treatment effect is better, the treatment way is convenient and fast, and the operation is easy.
Description
Technical field
The invention belongs to the animal medicament preparing technical field, be specifically related to a kind of animal compound ivermectin albendazole transdermal agent and use usage.
Background technology
In the livestock and poultry cultivation process, parasitic disease is many because of its cause of disease kind, distributes wide, and livestock and poultry breeding industry is had to larger impact.All kinds of parasites often endanger the health of animal in hidden mode, cause multiple chronic, the wasting diseases of poultry, not only affect growth, the growth of poultry, reduce quality and the quantity of animal products, but also can cause the large quantities of death of poultry, bring serious economic loss to aquaculture, some parasitic disease also can cause serious threat to people's health.In verminosis of animal, livestock and poultry cultivation is had the greatest impact and most importantly nematicide and external segmental appendage class parasite and cestode and trematodiasis in gastrointestinal tract.
In the last few years, the poultry various diseases comprises the parasitic disease increasingly complex, the phenomenon that the parasite mixed infection of number of different types often occurs, research and development for the treatment of single parasitic disease and prevention medicament in the past had been not suitable with new cultivation demand, the poultry medication that exploitation could prevent and the treat various diseases development trend that is inevitable.
The animal medicament common formulations has the types such as injection, tablet, powder, and injection easily produces stress in injection process, reduces the anti-power of supporting of animal self; And the bioavailability of tablet, powder main component is lower, palatability is poor; And transdermal agent because of it without liver first-pass effect, not affected by gastric emptying rate etc., bioavailability is high, easy to use, without pain, can cancel at any time or the plurality of advantages such as therapy discontinued is the hot fields of current animal medicament research and development, there is larger application value.
Ivermectin is the antibiotics antiparasitic of a kind of wide spectrum, efficient, low toxicity, to endoparasite and ectoparasite particularly nematicide and arthropod all have and well kill effect, but invalid to cestode, trematodiasis and protozoacide, or do not there is active function.In prior art, the preparation of ivermectin pharmacy type commonly used is injection and pre-mixing agent, in use easily cause the stress of animal as injection, reduce the resistance of animal self, and pre-mixing agent in use needs to mix with feedstuff, repeatedly feeds, increase human cost, present most feedstuff is composite material in addition, does not need to mix, and this also promotes the use of and brought difficulty for it.The broad-spectrum de-worming medicine that albendazole is a kind of high-efficiency low-toxicity, clinical in ascarifuge, pinworm, cestode, whipworm, ancylostome, excrement strongylid etc.The albendazole common formulations is tablet, and palatability is poor, and bioavailability is lower, has affected the therapeutic effect of Animal diseases.In conjunction with ivermectin and albendazole in the advantage separately aspect parasitic disease treatment and prevention, develop a kind of agreeable to the taste composite drug for animals and there is the meaning of outbalance, for these work, powder or injection have been developed, but as front said, dosage form often has larger impact to therapeutic effect, and there is not yet the relevant report of relevant this dosage form of research and development transdermal agent for this composite drug.
Summary of the invention
It is a kind of easy to use that the object of the invention is to provide, and for preventing and treat the animal compound ivermectin albendazole transdermal agent of animal parasitosis, and provides a kind of using method of this transdermal agent.
A kind of animal compound ivermectin albendazole transdermal agent, its constituent has: ivermectin, albendazole, solubilizing agent, transdermal enhancer, diluent;
Solubilizing agent is tween 80;
Transdermal enhancer is laurocapram;
The mixture that diluent is two or three arbitrary proportion in 95% ethanol, N-methyl-ketopyrrolidine, propylene glycol.
Described animal compound ivermectin albendazole transdermal agent, each constituent content is: ivermectin 0.5% ~ 5% (w/v), albendazole 5% ~ 50% (w/v), solubilizing agent 0.5% ~ 2%(v/v), transdermal agent 0.5% ~ 5% (v/v), diluent add to 100% (v/v).
Described animal compound ivermectin albendazole transdermal agent, each constituent content of optimum formula 1 is: ivermectin, 0.5% (w/v); Albendazole, 5% (w/v); Solubilizing agent: tween 80,0.5% (v/v); Transdermal enhancer: laurocapram, 3% (v/v); Diluent: N-methyl-ketopyrrolidine, 15% (v/v); 95% ethanol, 20% (v/v); Propylene glycol adds to 100% (v/v).
Described animal compound ivermectin albendazole transdermal agent, each constituent content of optimum formula 2 is: ivermectin, 1% (w/v); Albendazole, 10% (w/v); Solubilizing agent: tween 80,1.5% (v/v); Transdermal enhancer: laurocapram, 5% (v/v); Diluent: N-methyl-ketopyrrolidine, 20% (v/v); 95% ethanol, 20% (v/v); Propylene glycol adds to, 100% (v/v).
Animal compound ivermectin albendazole transdermal agent is used for the treatment of the parasitic disease of animal.
When described animal compound ivermectin albendazole transdermal agent is used for the treatment of the parasitic disease of animal, while pressing optimum formula 1 medication, pig is pressed the consumption of 0.06ml/kg, by evenly being pushed aside to both sides by hair of back, start the flow coat to root of the tail section along dorsal line by head, use continuously 3 days.
When described animal compound ivermectin albendazole transdermal agent is used for the treatment of the parasitic disease of animal, while pressing optimum formula 1 medication, sheep is pressed the consumption of 0.04ml/kg, by evenly being pushed aside to both sides by hair of back, start the flow coat to root of the tail section along dorsal line by head, use continuously 3 days.
When described animal compound ivermectin albendazole transdermal agent is used for the treatment of the parasitic disease of animal, while pressing optimum formula 2 medication, pig is pressed the consumption of 0.03ml/kg, by evenly being pushed aside to both sides by hair of back, start the flow coat to root of the tail section along dorsal line by head, use continuously 3 days.
When described animal compound ivermectin albendazole transdermal agent is used for the treatment of the parasitic disease of animal, while pressing optimum formula 2 medication, sheep is pressed the consumption of 0.02ml/kg, by evenly being pushed aside to both sides by hair of back, start the flow coat to root of the tail section along dorsal line by head, use continuously 3 days.
Animal compound ivermectin albendazole transdermal agent provided by the present invention, preparation method is simple, and compared to other dosage forms of the prior art, application method is simpler, convenient, and consumption is more economized; The Animal stress extent of reaction is low, and therapeutic modality is more convenient, easily operation; Through experimental comparison, therapeutic effect also has clear superiority than other dosage forms, has realized preferably the object of the invention.
The specific embodiment
Below in conjunction with embodiment the present invention will be further explained explanation.
embodiment 1
In the animal compound ivermectin albendazole transdermal agent product that the present embodiment provides, each constituent content is as follows:
Ivermectin, 0.5% (w/v); Albendazole, 5% (w/v);
Solubilizing agent: tween 80,0.5% (v/v);
Transdermal enhancer: laurocapram, 3% (v/v);
Diluent: N-methyl-ketopyrrolidine, 15% (v/v); 95% ethanol, 20% (v/v); Propylene glycol adds to 100% (v/v).
The preparation of the animal compound ivermectin albendazole transdermal agent of the present embodiment mainly comprises the following steps:
(1) get appropriate propylene glycol, be heated to 50～60 ℃, add the ivermectin of recipe quantity, stirring and dissolving, standby;
(2) get the N-methyl-ketopyrrolidine of recipe quantity, add the albendazole of recipe quantity, stirring and dissolving, standby;
(3) mix (1), (2) two solution, add 95% ethanol, the tween 80 of recipe quantity, stir, add propylene glycol to 100%;
(4) filter, fill, sterilizing, get product.
When the animal compound ivermectin albendazole transdermal agent that application the present embodiment provides is treated and is prevented and treated for the parasitic disease of pig, sheep, pig is pressed 0.06ml/kg, sheep is pressed the consumption of 0.04ml/kg, by evenly being pushed aside to both sides by hair of back, start the flow coat to root of the tail section along dorsal line by head, use continuously 3 days.
embodiment 2
In the animal compound ivermectin albendazole transdermal agent product that the present embodiment provides, each constituent content is as follows:
Ivermectin, 1% (w/v); Albendazole, 10% (w/v);
Solubilizing agent: tween 80,1.5% (v/v);
Transdermal enhancer: laurocapram, 5% (v/v);
Diluent: N-methyl-ketopyrrolidine, 20% (v/v); 95% ethanol, 20% (v/v); Propylene glycol adds to, 100% (v/v).
The preparation method of the preparation method of the animal compound ivermectin albendazole transdermal agent of the present embodiment and the animal compound ivermectin albendazole transdermal agent of embodiment 1 is similar, no longer be repeated in this description, but its preparation principle and key step is as follows:
(1) get appropriate diluent, as propylene glycol, add the ivermectin of recipe quantity, under felicity condition, stir and make its dissolving, standby;
(2) get the albendazole of recipe quantity, add appropriate diluent, under felicity condition, stir and make its dissolving, standby;
(3) blend step (1), (2) two solution, add the solubilizing agent of recipe quantity, stirs, and adds the diluent standardize solution;
(4) filter, fill, sterilizing, obtain finished product.
It should be noted that, for guaranteeing the product effect of animal compound ivermectin albendazole transdermal agent, in above-mentioned preparation process, diluent need be selected two or three different diluent, as for the proportioning between diluent be arbitrary proportion all can, but the minimum amount that at least needs guarantee to dissolve corresponding effective ingredient ivermectin or albendazole.
When the animal compound ivermectin albendazole transdermal agent that application the present embodiment provides is treated and is prevented and treated for the parasitic disease of pig, sheep, pig is pressed 0.03ml/kg, sheep is pressed the consumption of 0.02ml/kg, by evenly being pushed aside to both sides by hair of back, start the flow coat to root of the tail section along dorsal line by head, use continuously 3 days.
Product that above embodiment provides is all most preferred embodiment products of the present invention, and those skilled in the art carry out proper transformation to the proportioning of related component, according to prior art, can obtain the technical scheme that the present invention asks for protection, and therefore no longer is repeated in this description.
embodiment 3
For the product effect of of the present invention provided animal compound ivermectin albendazole transdermal agent is be provided, the inventor with
embodiment 2the animal compound ivermectin albendazole transdermal agent product provided is example, and its drug effect has been done to further contrast experiment.Test as follows:
The contrast medicine of drug effect check has respectively:
Ivermectin injection, the Zhejiang Haizheng Pharmaceutical Co, product batch number is, 20121211, specification is that 10ml/ props up, every containing ivermectin 0.5g;
Albendazole tablet, Henan Yawei Animal Medicine Co., Ltd., product batch number is 20120324-1, specification is 200mg/ sheet g;
Ivermectin albendazole powder, Henan Yawei Animal Medicine Co., Ltd., product batch number is 20120311-1, specification is the 100g/ bag, often comprises ivermectin 10g, albendazole 0.2g;
embodiment 2the animal compound ivermectin albendazole transdermal agent of preparation, specification is that 100ml/ props up, every containing ivermectin 1g, albendazole 10g.
Test method is as follows:
The piglet in 4～5 week age of making a definite diagnosis the serious Intestinal Nematode Infections of trouble of take is experimental animal, be divided at random 5 groups, i.e. compound ivermectin albendazole transdermal agent treatment group, folk prescription ivermectin injection group, folk prescription Albenza group, ivermectin albendazole powder group and blank group.
Every group 20 left and right morbidity piglets, administration time is continuous use 3 days, wherein the ivermectin injection dosage is the 0.3mg/Kg body weight, Albenza is counted the 8mg/Kg body weight with albendazole, compound ivermectin albendazole powder is counted the 1g/Kg body weight with this product, and compound ivermectin albendazole transdermal agent dosage is the 0.03ml/Kg body weight.The blank group is refused administration.After medication, continue to observe one week.
The judgement cure method: each group checks feces after treatment every day, until within continuous 2 days, detect negative being considered as of worm's ovum, cures.
Drug effect comparison test result is as shown in the table.
compound ivermectin albendazole transdermal agent of the present invention and normal injection and folk prescription medicine effect contrast test
| Grouping | Number of animals (only) | Dosage (mg/kg) | Administration time (d) | Cure rate (%) |
| Compound ivermectin albendazole transdermal agent treatment group | 23 | 0.03ml/kg | 3 | 100 |
| Compound ivermectin powder treatment group | 25 | 1g/kg | 3 | 90.2 |
| The ivermectin injection treatment group | 18 | 0.3mg/kg | 3 | 88.3 |
| The albendazole tablet treatment group | 25 | 8mg/kg | 3 | 85 |
To upper table analysis, can find out, ivermectin albendazole compound preparation is compared to single ivermectin or albendazole preparation, and because its antimicrobial spectrum is wider, therapeutic effect is also more outstanding; And compound ivermectin albendazole transdermal agent without liver first-pass effect, is not affected by gastric emptying rate etc., therapeutic effect the best due to it with respect to compound ivermectin albendazole powder.Transdermal agent is also more simple and convenient on occupation mode than powder or other dosage forms on occupation mode, has that Animal stress reaction is little, absorption efficiency is high and the advantage such as drug withdrawal at any time simultaneously, therefore has dissemination preferably.
Claims (8)
1. an animal compound ivermectin albendazole transdermal agent, is characterized in that, this transdermal agent constituent comprises: ivermectin, albendazole, solubilizing agent, transdermal enhancer, diluent;
Solubilizing agent is tween 80;
Transdermal enhancer is laurocapram;
The mixture that diluent is two or three arbitrary proportion in 95% ethanol, N-methyl-ketopyrrolidine, propylene glycol.
2. animal compound ivermectin albendazole transdermal agent as claimed in claim 1, it is characterized in that, each constituent content of this transdermal agent is: ivermectin 0.5% ~ 5% (w/v), albendazole 5% ~ 50% (w/v), solubilizing agent 0.5% ~ 2%(v/v), transdermal agent 0.5% ~ 5% (v/v), diluent add to 100% (v/v).
3. animal compound ivermectin albendazole transdermal agent as claimed in claim 2, is characterized in that, each constituent content of this transdermal agent is: ivermectin, 0.5% (w/v); Albendazole, 5% (w/v); Solubilizing agent: tween 80,0.5% (v/v); Transdermal enhancer: laurocapram, 3% (v/v); Diluent: N-methyl-ketopyrrolidine, 15% (v/v); 95% ethanol, 20% (v/v); Propylene glycol adds to 100% (v/v).
4. animal compound ivermectin albendazole transdermal agent as claimed in claim 2, is characterized in that, each constituent content of this transdermal agent is: ivermectin, 1% (w/v); Albendazole, 10% (w/v); Solubilizing agent: tween 80,1.5% (v/v); Transdermal enhancer: laurocapram, 5% (v/v); Diluent: N-methyl-ketopyrrolidine, 20% (v/v); 95% ethanol, 20% (v/v); Propylene glycol adds to, 100% (v/v).
5. when the described animal compound ivermectin of claim 3 albendazole transdermal agent is used for the treatment of the parasitic disease of pig, press the 0.06ml/kg consumption, by evenly being pushed aside to both sides by hair of back, along dorsal line, by head, start the flow coat to root of the tail section, use continuously 3 days.
6. when the described animal compound ivermectin of claim 3 albendazole transdermal agent is used for the treatment of the parasitic disease of sheep, press the 0.04ml/kg consumption, by evenly being pushed aside to both sides by hair of back, along dorsal line, by head, start the flow coat to root of the tail section, use continuously 3 days.
7. when the described animal compound ivermectin of claim 4 albendazole transdermal agent is used for the treatment of the parasitic disease of pig, press the 0.03ml/kg consumption, by evenly being pushed aside to both sides by hair of back, along dorsal line, by head, start the flow coat to root of the tail section, use continuously 3 days.
8. when the described animal compound ivermectin of claim 4 albendazole transdermal agent is used for the treatment of the parasitic disease of sheep, press the 0.02ml/kg consumption, by evenly being pushed aside to both sides by hair of back, along dorsal line, by head, start the flow coat to root of the tail section, use continuously 3 days.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310453797.6A CN103494832B (en) | 2013-09-29 | 2013-09-29 | A kind of compound ivermectin albendazole transdermal agent for livestock and using method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310453797.6A CN103494832B (en) | 2013-09-29 | 2013-09-29 | A kind of compound ivermectin albendazole transdermal agent for livestock and using method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103494832A true CN103494832A (en) | 2014-01-08 |
| CN103494832B CN103494832B (en) | 2015-12-09 |
Family
ID=49860156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310453797.6A Active CN103494832B (en) | 2013-09-29 | 2013-09-29 | A kind of compound ivermectin albendazole transdermal agent for livestock and using method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103494832B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108125973A (en) * | 2016-11-30 | 2018-06-08 | 黎凯华 | A kind of insecticidal preparation containing ivermectin |
| CN108125971A (en) * | 2016-11-30 | 2018-06-08 | 黎凯华 | A kind of ivermectin composition insecticidal preparation |
| CN108125972A (en) * | 2016-11-30 | 2018-06-08 | 黎凯华 | A kind of Chinese and Western compound insecticidal preparation |
| CN109568248A (en) * | 2019-01-23 | 2019-04-05 | 天津软银科技有限公司 | A kind of animal compound preparation capable of permeating skin |
| CN112294831A (en) * | 2020-11-11 | 2021-02-02 | 宁波科瑞特动物药业有限公司 | Transdermal drop for expelling parasites on animals and preparation method thereof |
| CN114917221A (en) * | 2022-05-27 | 2022-08-19 | 吉林吉力生物技术研究有限公司 | Veterinary albendazole sulfoxide composition as well as preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101579309A (en) * | 2009-06-23 | 2009-11-18 | 天津必佳药业集团有限公司 | Anti-parasitic ivermectin transdermal solution used for livestock and preparation method thereof |
| CN102440944A (en) * | 2010-10-08 | 2012-05-09 | 内蒙古农业大学 | Ivermectin transdermal liniment for animals |
-
2013
- 2013-09-29 CN CN201310453797.6A patent/CN103494832B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101579309A (en) * | 2009-06-23 | 2009-11-18 | 天津必佳药业集团有限公司 | Anti-parasitic ivermectin transdermal solution used for livestock and preparation method thereof |
| CN102440944A (en) * | 2010-10-08 | 2012-05-09 | 内蒙古农业大学 | Ivermectin transdermal liniment for animals |
Non-Patent Citations (1)
| Title |
|---|
| 陈红伟 等: "正交设计筛选复方伊维菌素透皮剂处方", 《黑龙江畜牧兽医》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108125973A (en) * | 2016-11-30 | 2018-06-08 | 黎凯华 | A kind of insecticidal preparation containing ivermectin |
| CN108125971A (en) * | 2016-11-30 | 2018-06-08 | 黎凯华 | A kind of ivermectin composition insecticidal preparation |
| CN108125972A (en) * | 2016-11-30 | 2018-06-08 | 黎凯华 | A kind of Chinese and Western compound insecticidal preparation |
| CN109568248A (en) * | 2019-01-23 | 2019-04-05 | 天津软银科技有限公司 | A kind of animal compound preparation capable of permeating skin |
| CN112294831A (en) * | 2020-11-11 | 2021-02-02 | 宁波科瑞特动物药业有限公司 | Transdermal drop for expelling parasites on animals and preparation method thereof |
| CN114917221A (en) * | 2022-05-27 | 2022-08-19 | 吉林吉力生物技术研究有限公司 | Veterinary albendazole sulfoxide composition as well as preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103494832B (en) | 2015-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103494832B (en) | A kind of compound ivermectin albendazole transdermal agent for livestock and using method thereof | |
| Adaszek et al. | Properties of capsaicin and its utility in veterinary and human medicine | |
| CN102670516A (en) | Tilmicosin soluble powder and preparation method thereof | |
| EA017656B1 (en) | Composition for prevention and treatment of pig dysentery | |
| CN101450068A (en) | Premixing agent for preventing and treating livestock nematodiasis | |
| CN103479658A (en) | Maduramicin ammonium nicarbazin premix and preparation method thereof | |
| CN103977017A (en) | Anti-parasitic injection for veterinary use and preparation method thereof | |
| CN104800167A (en) | Florfenicol soluble powder and preparation method thereof | |
| CN102499973B (en) | Compound propolis composition for treating dog and cat scabies and preparation method thereof | |
| Lindholm et al. | Comparison of deslorelin and histrelin for induction of ovulation in mares | |
| CN105963688A (en) | Powder for curing intestinal diseases of piglet and enhancing immunity and preparation method thereof | |
| CN102274318A (en) | Pure traditional Chinese medicine composition for treating poultry coccidiosis and preparation method thereof | |
| CN101947203A (en) | Valnemulin hydrochloride emulsion for animals and preparation method thereof | |
| CN102755337B (en) | Compound florfenicol injection and preparation method thereof | |
| CN102429918A (en) | Medicinal composition containing florfenicol and tea saponin and preparation method thereof | |
| DE2640322A1 (en) | MEDICAL PREPARATION CONTAINING ADRENAL CORDLIC HORMONE AND A THYROID-STIMULATING HORMONE RELEASING HORMONE | |
| CN102755342B (en) | Compound paracetamol injection and preparation method thereof | |
| CN106620668A (en) | Compound tilmicosin solid dispersing agent and preparation method thereof | |
| CN102961405A (en) | Secretio bufonis injection for treating yellow and white scour of newborn piglets, and preparation method of injection | |
| CN101991587A (en) | Compound sulfadiazine injection and preparation method thereof | |
| CN106539754A (en) | Hydrobromic acid antifebrile dichroanone solution and preparation method thereof | |
| CN101301274B (en) | Compound mequindox soluble powder for animals and preparation thereof | |
| CN101966201A (en) | Compound norfloxacin nicotinic soluble powder and preparation method thereof | |
| CN103417477B (en) | A kind of take water as doractin O/W type injection of substrate and preparation method thereof | |
| US6552063B2 (en) | Phenylbutazone carrier formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |